The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients

ConditionMCI

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age55+

SponsorBeni-Suef University

About this trial

The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

T2DM adult subjects (>55 years old) will be eligible to participate.

Patients should be taking SGLT2Is+metformin or DDP4Is + metformin for at least 1 year to be eligible.

Disqualifiers

None

Trial population

T2DM patients (aged above 55 years)

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

SGLT2 Is+METFORMIN
Drug
Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months
DPP4 Is+metformin
Drug
Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months
Control group
Drug
patients administered their standard of care without any changes for the past 6 months

Treatment groups

300 Participants

are divided into 3 treatment groups

Group A: SGLT2 I Group1 intervention

Group B: DPP4I group1 intervention

Group C: Control group1 intervention

Trial outcomes

Primary outcomes

MCI

Changes in Montreal Cognitive Assessment (MoCA) score

Time frame

Day 1

Depression

Changes in Patient Health Questionnaire-9 (PHQ-9) score

Time frame

Day 1

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beni-Suef University

Lead sponsor

Source ClinicalTrials.gov

Apply now